ViewRay signs agreement with GenesisCare to bring the first MRIdian MRI-guided radiotherapy systems to the UK

New agreement expands access to precision radiotherapy for people with cancer

ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients.

As part of the formal agreement, multiple MRIdian linear accelerators will be deployed within the GenesisCare network, with the first two systems to be installed in the UK. MRIdian leverages the soft- tissue imaging capabilities of MRI to allow oncologists to visualise tumours and personalise treatment more accurately than is possible with conventional technology. The agreement will allow GenesisCare to advance its vision of precision radiation medicine by contributing to the evidence base for, and delivering, high quality image-guided, adaptive radiotherapy.

“GenesisCare is continually exploring how technology can help us to deliver better outcomes for people with cancer,” said Aldo Rolfo, Executive Manager for GenesisCare Europe. “Combining an MRI scanner with a linear accelerator is the way of the future in radiotherapy, allowing us to see – for the first time – what’s really happening inside the body during treatment. This will enable our clinicians to offer truly personalised radiotherapy by adapting treatment in real-time, to better target tumours and minimise side effects for patients.”

With more than 130 oncology and cardiology centres in total, GenesisCare offers radiotherapy at 12 centres in the United Kingdom, 21 centres in Spain and 30 centres in Australia. Every year more than 160,000 people from around the world receive care through GenesisCare’s team of more than 2,500 highly trained healthcare professionals and support staff.

“We’re excited to partner with GenesisCare to bring the important clinical benefits of MRIdian MRI- guided radiotherapy to cancer patients in the UK and around the world,” said Scott Drake, President and CEO of ViewRay. “The reach of the GenesisCare network is vast and their investment in MRIdian is a testament to its industry leading innovation for on-table adaptive therapy. We are proud to be revolutionising the field of radiation oncology.”

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to future MRIdian installations, clinical value and outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at

Related articles

Honouring Clinical Excellence & Leadership: GenesisCare Launches Inaugural Global Physician Recognition Program

GenesisCare Appoints Seven Leading Oncologists to Chair its Global Research Committees

SABR Consortium Annual Professional Conference 2021

Annual research report 2020